SkinSight™ AI by ModuleMD: Smarter Skin Analysis, Faster Clinical Decisions

GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ — ModuleMD, ranked as one of America’s fastest-growing companies on the Inc. 5000 and top-rated EHR vendor on G2, announces SkinSight™ AI, a solution that brings automation, accuracy, and consistency to one of the most manual and variable workflows in allergy care: skin test measurement and documentation.

For years, allergy practices have been expected to deliver better documentation, clearer outcomes, and stronger patient communication while reimbursement remains unchanged.

SkinSight™ AI introduces a new era of standardization that meets these growing operational demands without adding work, steps, or hardware.

Why SkinSight™ AI Matters Today

Allergy skin testing remains highly subjective, often relying on staff experience, manual measurement, and individual interpretation. SkinSight™ AI removes these inconsistencies and replaces them with an objective, data-driven process designed for accuracy, efficiency, and trust.

SkinSight™ AI delivers:

  1. More objective and consistent measurements
    Standardizes grading across staff, days, and clinic locations, reducing human variability and ensuring every reaction is evaluated the same way.
  2. Increased accuracy in identifying wheal and flare boundaries
    Precisely detects subtle and irregular reactions that are difficult for the human eye to measure.
  3. Saves time during the patient visit
    Automates measurement and grading in seconds, freeing up several minutes per test without changing workflow.
  4. Automatically documents results to the patient record
    Structured, time-stamped measurements and images flow directly into the EHR, eliminating manual entry and reducing errors.
  5. Supports research and outcomes analysis
    Aggregates usable data for trend studies, protocol refinement, and practice-driven clinical research.
  6. Builds patient trust in test results
    Transparent measurements and visuals make results easier for patients to understand and increase confidence in the care they receive.
  7. Enables review of test results later
    Improves follow-up conversations by allowing clinicians to revisit past results with clarity and precision.
  8. Allows visual timeline comparisons
    Tracks reaction progression over time to support treatment decisions, therapy adjustments, and patient education.

How SkinSight™ AI Works

After the skin test panel is placed, staff simply captures an image using the device they already have. SkinSight™ AI instantly:

  • Detects positive reactions
  • Measures wheal and flare size
  • Identifies clinically meaningful responses
  • Documents structured results directly into the patient chart

No new steps. No new hardware. No retraining.

Building the Future of Data-Driven Allergy Care

SkinSight™ AI is the foundation for long-term innovation in allergy testing. Upcoming capabilities will include:

  • Longitudinal comparisons across visits
  • Trend analysis to monitor treatment impact
  • Medication-response insights for more tailored care

These enhancements will empower practices to move beyond subjective measurement and towards measurable, outcomes-based allergy care.

Supporting Practices Amid CPT 95004 Pressure

With reimbursement for CPT 95004 remaining flat, allergy practices must find ways to optimize accuracy and efficiency without increasing labour. SkinSight™ AI helps bridge this gap by:

  • Reducing manual workload
  • Standardizing documentation
  • Supporting outcomes reporting and transparency

A Platform Built for Modern Allergy, Immunotherapy, and Biologic Care

ModuleMD, ranked among America’s fastest-growing companies on the Inc. 5000 and highly rated on G2, is more than an EHR vendor. They are a specialty-driven platform that runs Allergy/ Immunotherapy, and Biologics workflows directly within the EMR itself.

SkinSight™ AI is the latest example of ModuleMD’s mission: building purpose-built tools that reduce clinical burden, standardize treatment, support precision therapy, and strengthen patient trust all inside one connected allergy platform. To know more on ModuleMD, visit www.modulemd.com

SkinSight™ Patent Pending*
(*Asterisk intentionally added to mark proprietary branding.)

Logo: https://healthtechnologynet.com/wp-content/uploads/2025/12/Module_MD_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/skinsight-ai-by-modulemd-smarter-skin-analysis-faster-clinical-decisions-302635235.html

SOURCE ModuleMD Healthcare Solutions Private Limited

Staff

Recent Posts

TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026

Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

2 hours ago

TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026

Vancouver, British Columbia--(Newsfile Corp. - January 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

2 hours ago

Orlando Health Network created new care models in 2025 amid growth outside Central Florida

Annual report also details how multi-state clinically integrated network generated nearly $544 million in healthcare…

7 hours ago

SHINE Completes Acquisition of Lantheus SPECT Business, Names Michael Rossi SHINE SPECT CEO

SHINE acquires Billerica manufacturing facility and established SPECT product portfolio, expanding leadership in nuclear medicineJANESVILLE,…

7 hours ago

MarathonLS and Pacer Announce Strategic Separation into Two Independent Organizations

BOSTON, Jan. 2, 2026 /PRNewswire/ -- Today, MarathonLS announces the strategic separation of its segments into…

7 hours ago

Caring for Caregivers: DaVita’s Investment in Nursing Education and Growth

NORTHAMPTON, MA / ACCESS Newswire / January 2, 2026 / As chronic disease rates climb[1],…

7 hours ago